MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LENZ had -$12,323K decrease in cash & cash equivalents over the period. -$9,027K in free cash flow.

Cash Flow Overview

Change in Cash
-$12,323K
Free Cash flow
-$9,027K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-16,700 -29,531
Depreciation and amortization
125 55
Loss on impairment of operating right-of-use assets and related property and equipment
0 82
Accretion of discounts on marketable securities
779 2,022
Change in fair value of preferred stock warrants
0 0
Share-based compensation expense
3,469 5,400
Inventory
949 -
Prepaid expenses and other current assets
-93 1,196
Accounts payable
1,694 -1,628
Accrued liabilities
4,459 1,487
Other assets
0 204
Net cash used in operating activities
-8,588 -27,557
Purchases of marketable securities
56,306 91,385
Proceeds from maturities of marketable securities
52,412 110,210
Purchases of property and equipment
439 350
Net cash provided by (used in) investing activities
-4,333 18,475
Proceeds from issuance of common stock, net of issuance costs-At The Market Offerings
0 26,067
Proceeds from exercises of stock options
598 240
Proceeds from issuance of common stock under employee stock purchase plan
0 225
Cash, cash equivalents, and restricted cash acquired in connection with the merger
0 0
Proceeds from issuance of common stock, net of issuance costs-Private Placement
0 0
Merger transaction costs
0 0
Net cash provided by financing activities
598 26,532
Net increase in cash, cash equivalents, and restricted cash
-12,323 17,450
Cash and cash equivalents at beginning of period
20,272 -
Cash and cash equivalents at end of period
25,399 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. (LENZ)